Xeroderma pigmentosum (XP) is a rare genodermatosis characterized by
defective DNA repair, leading to hypersensitivity to ultraviolet (UV)
sunlight and predisposes to various cutaneous and non-cutaneous
malignancies. Platinum compounds are used against cutaneous cancers as
concurrent chemoradiotherapy. But the XP gene polymorphism has a
potential role in metabolism of these agents and their susceptibility.
Here, we report a case of cutaneous squamous cell carcinoma in a patient
with XP who had severe toxicity to chemotherapy. We also discuss other
similar cases reported in literature of this entity, to highlight this
potentially lethal pharmacogenomic association.